7-117535293-G-T
Variant summary
Our verdict is Uncertain significance. The variant received 3 ACMG points: 3P and 0B. PM1PP2
The NM_000492.4(CFTR):c.625G>T(p.Ala209Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000781 in 1,613,558 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A209V) has been classified as Uncertain significance.
Frequency
Consequence
NM_000492.4 missense
Scores
Clinical Significance
Conservation
Publications
- cystic fibrosisInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), Myriad Women’s Health, Orphanet
- congenital bilateral absence of vas deferensInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary chronic pancreatitisInheritance: AD Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.625G>T | p.Ala209Ser | missense_variant | Exon 6 of 27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151710Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000119 AC: 3AN: 251444 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.0000848 AC: 124AN: 1461848Hom.: 0 Cov.: 32 AF XY: 0.0000743 AC XY: 54AN XY: 727228 show subpopulations
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151710Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74090 show subpopulations
ClinVar
Submissions by phenotype
Cystic fibrosis Uncertain:2Other:1
This sequence change replaces alanine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 209 of the CFTR protein (p.Ala209Ser). This variant is present in population databases (rs397508772, gnomAD 0.003%). This missense change has been observed in individual(s) with clinical features of CFTR-related conditions (PMID: 11379874, 16134171, 17035430, 34782259). ClinVar contains an entry for this variant (Variation ID: 54030). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt CFTR protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change does not substantially affect CFTR function (PMID: 15504721). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
The p.A209S variant (also known as c.625G>T), located in coding exon 6 of the CFTR gene, results from a G to T substitution at nucleotide position 625. The alanine at codon 209 is replaced by serine, an amino acid with similar properties. An individual diagnosed with idiopathic chronic pancreatitis was reported to be heterozygous for this variant (Cohn et al. Hum Mut. 2005:26(4):303-7). Another study reported an individual who was heterozygous for this variant diagnosed with bronchiectasis (Ziedalski et al. Chest. 2006:130(4):995-1002). This amino acid position is poorly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
not specified Uncertain:1
Variant summary: CFTR c.625G>T (p.Ala209Ser) results in a conservative amino acid change located in the transmembrane domain (IPR011527) of the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 251444 control chromosomes. c.625G>T has been reported in the literature in individuals affected with Cystic Fibrosis, ICP, bronchiectasis and infertility, without strong evidence for causality (LeMarechal_2001, Cohn_2005, Ziedalski_2006, Oud_2017). These data do not allow any conclusion about variant significance. In at least one individual with Cystic Fibrosis, the variant was identified along with two other co-occurring pathogenic variants (CFTR c.1521_1523del, p.F508del; CFTR c.366T>A, p.Y122*), providing supporting evidence for a benign role (Raraigh_2022). One experimental study showed single channel conductance similar to that of wild-type (Ge_2004) while another showed approximately 30% of normal chloride channel conductance relative to wild type (e.g., Bihler_2024). The following publications have been ascertained in the context of this evaluation (PMID: 16134171, 15504721, 11379874, 28801929, 25735457, 34782259, 17035430, 38388235). ClinVar contains an entry for this variant (Variation ID: 54030). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. -
CFTR-related disorder Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at